# **OPAT Delivery during COVID-19**

Michael Swartwood, BSN, RN, CAPM<sup>1</sup> Renae Boerneke, PharmD, BCPS<sup>4</sup> Alan C. Kinlaw, PhD, MSPH<sup>2,3</sup> Nikolaos Mavrogiorgos, MD<sup>1</sup> Ashley H Marx, PharmD <sup>4,5</sup> Emily J Ciccone, MD, MHS<sup>1</sup> Asher J Schranz, MD, MPH<sup>1</sup> Mary Catherine Bowman, MD, PhD<sup>1</sup> Claire E. Farel, MD, MPH<sup>1</sup>


<sup>1</sup>Division of Infectious Diseases, University of North Carolina (UNC) School of Medicine **2** Division of Pharmaceutical Outcomes and Policy, UNC School of Pharmacy <sup>3</sup>Cecil G. Sheps Center for Health Services Research, UNC-Chapel Hill I <sup>4</sup>UNC Health I <sup>5</sup>UNC Eshelman School of Pharmacy

### BACKGROUND

- In 2020, COVID-19 spurred unprecedented change in the delivery of routine clinical care.
- The UNC OPAT program staff, previously accustomed to in-person collaboration in the hospital, became geographically distant amid North Carolina's partial shutdown starting in March 2020.
- Team members relied on teleworking and many **OPAT** clinic visits were shifted to phone and video telehealth.
- We assessed how COVID-19 impacted our care of OPAT patients including follow-up visits and readmissions.

# **METHODS**

- OPAT patients are evaluated by an infectious diseases (ID) physician, have a planned antimicrobial duration of at least 14 days, and receive specialized monitoring led by an ID pharmacist
- UNC's OPAT database contains clinical and demographic information on all OPAT patients
- For all OPAT courses that ended between 3/1/20 and 5/20/20, we assessed the length of OPAT treatment course, readmissions, adverse events, follow-up ID clinic visits, and the method of follow-up visit utilized.
- We compared these measurements to historical baseline data from 3/1/19 to 5/20/19.



Length Mode of

Type

In Pers

Telepho

Telehea

UNC's OPAT program continued to provide high quality patient care during the first months of the COVID-19 pandemic by adapting its care delivery and follow-up visit protocols to include virtual care options.

- data.



RESULTS

**TABLE 1: Cohort Comparison**

acteristic	2019 Cohort (N=70 Patients)	2020 Cohort (N=73 Patients)
ent of patients who attended follow-up ntment with infectious disease specialist	93%	85%
h of OPAT course (median)	35 days	36 days
of follow-up visits	All conducted in-person	Mixture of in-person, via telehealth video solutions, and via phone

# TABLE 2: 2020 Cohort: Method of Follow Up Appointment

	nt of Visits nducted
son 26	42%
none Visit 28	45%
ealth Video Visit 8	13%

# **CONCLUSIONS & IMPLICATIONS**

Readmission rates for OPAT patients during COVID-19 were comparable to historical baseline

# These data highlight the utility of a multidisciplinary team-based strategy in care of OPAT patients and continued opportunity for use of telehealth for OPAT.

Future interventions and research should address appropriate expansion of virtual care opportunities and reimbursement structures to enhance patient care.

# **SCHOOL OF MEDICINE ESHELMAN SCHOOL OF PHARMACY**



#### **TABLE 3:** Rates of Hospital **Readmission During OPAT**

2020 Cohort (N=73)	16%
2019 Cohort (N=70)	14%
	P=0.72

# LIMITATIONS

 Patients in UNC's OPAT program are a selected subset of UNCMC patients who are discharged on intravenous antimicrobial therapy.

#### **DISCLOSURES**

Alan Kinlaw received funding support from National Research Service Award Post-Doctoral Traineeship from the Agency for Healthcare Research and Quality, sponsored by the Cecil G. Sheps Center for Health Services Research at UNC Chapel Hill (5T32 HS000032-28). Asher Schranz received funding support from the National Institute on Drug Abuse (K23DA049946)

Contact: Michael Swartwood, BSN, RN, CAPM mjswartw@med.unc.edu